Contact
searchSearch
HMP Global
Login

FGFR News

FDA Approval
FDA Approves Erdafitinib for Patients With Locally Advanced/Metastatic Urothelial Carcinoma Harboring FGFR3 Alterations
01/20/2024
Based on results from cohort 1 of the BLC3001 study, the FDA has approved erdafitinib for patients with locally advanced/metastatic urothelial carcinoma harboring FGFR3 alterations.
Based on results from cohort 1 of the BLC3001 study, the FDA has approved erdafitinib for patients with locally advanced/metastatic urothelial carcinoma harboring FGFR3 alterations.
Based on results from cohort 1...
01/20/2024
Oncology
News
Pemigatinib Effective, Safe Among Patients With Unresectable or Metastatic Urothelial Carcinoma With FGFR3 Genetic Alterations
12/19/2023
Final results from the phase 2 FIGHT-201 trial found pemigatinib demonstrated clinical activity and tolerable safety among patients with unresectable or metastatic urothelial carcinoma with FGFR3 genetic alterations.
Final results from the phase 2 FIGHT-201 trial found pemigatinib demonstrated clinical activity and tolerable safety among patients with unresectable or metastatic urothelial carcinoma with FGFR3 genetic alterations.
Final results from the phase 2...
12/19/2023
Oncology
News
Erdafitinib Prolonged Overall Survival Among Patients With FGFR-Altered Metastatic Urothelial Carcinoma Treated With Checkpoint Inhibitors
12/01/2023
According to the phase 3 THOR trial, erdafitinib prolonged overall survival among patients with FGFR-altered metastatic urothelial carcinoma who had previously received treatment with anti–PD-1/L1 agents, compared with chemotherapy.
According to the phase 3 THOR trial, erdafitinib prolonged overall survival among patients with FGFR-altered metastatic urothelial carcinoma who had previously received treatment with anti–PD-1/L1 agents, compared with chemotherapy.
According to the phase 3 THOR...
12/01/2023
Oncology
News
Pemigatinib Shows Potential for First Effective Treatment for FGFR1-Mutant Myeloid, Lymphoid Neoplasms
03/09/2022
Results of the ongoing FIGHT-203 trial show pemigatinib for FGFR1-mutant myeloid and lymphoid neoplasms may be a bridge for HSCT or a long-term treatment option for those ineligible for transplant.
Results of the ongoing FIGHT-203 trial show pemigatinib for FGFR1-mutant myeloid and lymphoid neoplasms may be a bridge for HSCT or a long-term treatment option for those ineligible for transplant.
Results of the ongoing FIGHT-203...
03/09/2022
Oncology
News
Pan-FGFR TKI Shows Favorable Efficacy in Advanced Urothelial Cancer
02/25/2022
Erdafitinib continues to show efficacy with longer follow-up for patients with locally advanced or metastatic urothelial carcinoma and prespecified FGFR alterations.
Erdafitinib continues to show efficacy with longer follow-up for patients with locally advanced or metastatic urothelial carcinoma and prespecified FGFR alterations.
Erdafitinib continues to show...
02/25/2022
Oncology
News
Pemigatinib, A Selective FGFR Inhibitor, Safely Treats Hematologic Malignancies
02/23/2022
Results from the FIGHT-101 trial confirm pemigatinib was safe and tolerable in patients with FGFR mutant hematologic malignancies. These findings prompted phase 2/3 trials in multiple tumors that will benefit from this precision therapy.
Results from the FIGHT-101 trial confirm pemigatinib was safe and tolerable in patients with FGFR mutant hematologic malignancies. These findings prompted phase 2/3 trials in multiple tumors that will benefit from this precision therapy.
Results from the FIGHT-101 trial...
02/23/2022
Oncology

Recent News

News
Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer
11/14/2024
According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.
According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.
According to a retrospective...
11/14/2024
Oncology
News
Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer
11/14/2024
According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.
According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.
According to results from the...
11/14/2024
Oncology
News
Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma
11/13/2024
Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.
Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.
Results from the phase 2...
11/13/2024
Oncology
News
Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas
11/12/2024
According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...
According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...
According to a phase 2b trial,...
11/12/2024
Oncology
News
Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer
11/12/2024
According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.
According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.
According to final results from...
11/12/2024
Oncology
News
Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer
11/11/2024
According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.
According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.
According to results from a...
11/11/2024
Oncology
FDA Approval
FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia
11/08/2024
On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
On November 8, 2024, the FDA...
11/08/2024
Oncology
News
Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer
11/07/2024
While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.
While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.
While naporafenib plus...
11/07/2024
Oncology
News
Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer
11/06/2024
According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.
According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.
According to results from a...
11/06/2024
Oncology
News
Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma
11/05/2024
A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.
A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.
A single-center real-world study...
11/05/2024
Oncology

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use